Isis Pharmaceuticals Announces Plan Investigate Higher Dose of ISIS-SMN Rx in Children with Spinal Muscular Atrophy

Loading...
Loading...
Isis Pharmaceuticals
ISIS
announced today that it plans to add a 12 mg cohort to the ongoing Phase 1b/2a study evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA).  In addition, a 12 mg dose will be included in an open-label extension study for those children who have completed dosing in previous studies.  The addition of the 12 mg cohort will allow for the investigation of this dose in support of the Phase 2/3 registration-directed program planned to begin next year.   "We are pleased to be able to increase the dose of ISIS-SMNRx based on the safety and tolerability data we have seen to date in both infants and children with SMA.  We have already begun the infant 12 mg dose cohort and look forward to sharing data from this study early next year.  Considering the encouraging safety profile we have observed in children with SMA in the lower dose cohorts, the evaluation of the 12 mg dose will provide additional information as we move into our Phase 3 program.  We are also pleased that after reviewing the data, the FDA agrees that we can proceed in our investigation of a
See full press release
Posted In: NewsGuidanceGlobal
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...